 ANDOVER, Mass., June 10, 2021 PRNewswire -- TransMedics Group, Inc. TransMedics Nasdaq: TMDX, a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the U.S. Food and Drug Administration FDA has announced the scheduling of a public advisory committee meeting during which it will review information regarding TransMedics premarket approval application for the OCS Liver System. 